AU619027B2 - Method for suppressing immune responses by administering imexon - Google Patents

Method for suppressing immune responses by administering imexon Download PDF

Info

Publication number
AU619027B2
AU619027B2 AU38877/89A AU3887789A AU619027B2 AU 619027 B2 AU619027 B2 AU 619027B2 AU 38877/89 A AU38877/89 A AU 38877/89A AU 3887789 A AU3887789 A AU 3887789A AU 619027 B2 AU619027 B2 AU 619027B2
Authority
AU
Australia
Prior art keywords
imexon
salt
treated
proliferation
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU38877/89A
Other languages
English (en)
Other versions
AU3887789A (en
Inventor
Uwe Bicker
Elmar Bosies
Rainer Haag
Dieter Herrmann
Wolfgang Kampe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AUTOONCONA PHARMA GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Publication of AU3887789A publication Critical patent/AU3887789A/en
Application granted granted Critical
Publication of AU619027B2 publication Critical patent/AU619027B2/en
Assigned to ROCHE DIAGNOSTICS GMBH reassignment ROCHE DIAGNOSTICS GMBH Request to Amend Deed and Register Assignors: BOEHRINGER MANNHEIM GMBH
Assigned to AUTOONCONA PHARMA GMBH reassignment AUTOONCONA PHARMA GMBH Alteration of Name(s) in Register under S187 Assignors: ROCHE DIAGNOSTICS GMBH
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU38877/89A 1988-07-28 1989-07-24 Method for suppressing immune responses by administering imexon Ceased AU619027B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3825667A DE3825667A1 (de) 1988-07-28 1988-07-28 Verwendung von imexon als immunsuppressivum
DE3825667 1988-07-28

Publications (2)

Publication Number Publication Date
AU3887789A AU3887789A (en) 1990-02-01
AU619027B2 true AU619027B2 (en) 1992-01-16

Family

ID=6359767

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38877/89A Ceased AU619027B2 (en) 1988-07-28 1989-07-24 Method for suppressing immune responses by administering imexon

Country Status (14)

Country Link
EP (1) EP0352652B1 (enExample)
JP (1) JP2848634B2 (enExample)
KR (1) KR0135757B1 (enExample)
AT (1) ATE117551T1 (enExample)
AU (1) AU619027B2 (enExample)
CA (1) CA1333771C (enExample)
DE (2) DE3825667A1 (enExample)
DK (1) DK175199B1 (enExample)
HU (1) HU206827B (enExample)
IE (1) IE66680B1 (enExample)
IL (1) IL91138A (enExample)
PH (1) PH26684A (enExample)
PT (1) PT91293B (enExample)
ZA (1) ZA895710B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0416870A (pt) * 2003-12-08 2007-01-30 Univ Arizona composições anticáncer sinergìticas

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1559676A (en) * 1975-07-08 1978-01-12 FOEHRINGER MANNHEIM Gmbh Diaza bicyclo compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2528460A1 (de) * 1975-06-26 1977-01-13 Boehringer Mannheim Gmbh Verwendung von l-carboxamido-2- cyan-aziridin als immunstimulans
DE2736296A1 (de) * 1977-08-12 1979-02-22 Boehringer Mannheim Gmbh Verwendung von 2-cyan-aziridin und seinen derivaten zur immunstimulierung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1559676A (en) * 1975-07-08 1978-01-12 FOEHRINGER MANNHEIM Gmbh Diaza bicyclo compounds

Also Published As

Publication number Publication date
DK363389A (da) 1990-01-29
EP0352652A2 (de) 1990-01-31
IE66680B1 (en) 1996-01-24
DE3825667A1 (de) 1990-03-15
IL91138A0 (en) 1990-03-19
DK175199B1 (da) 2004-07-05
HUT52378A (en) 1990-07-28
CA1333771C (en) 1995-01-03
ZA895710B (en) 1990-04-25
KR900001369A (ko) 1990-02-27
PT91293B (pt) 1995-03-01
EP0352652B1 (de) 1995-01-25
KR0135757B1 (ko) 1998-04-23
AU3887789A (en) 1990-02-01
DE58908926D1 (de) 1995-03-09
DE3825667C2 (enExample) 1991-06-27
PH26684A (en) 1992-09-15
DK363389D0 (da) 1989-07-21
ATE117551T1 (de) 1995-02-15
HU206827B (en) 1993-01-28
IE892448L (en) 1990-01-28
PT91293A (pt) 1990-02-08
JPH0288521A (ja) 1990-03-28
EP0352652A3 (de) 1991-09-04
IL91138A (en) 1994-10-21
JP2848634B2 (ja) 1999-01-20

Similar Documents

Publication Publication Date Title
JP4382164B2 (ja) 求核性置換エクテイナシジン類およびn−オキシドエクテイナシジン類
JPS62240619A (ja) 制癌剤
JPH0662407B2 (ja) 安定化された3―オキシゲルミルプロピオン酸ポリマーを有効成分とする免疫調整剤
JPH02502826A (ja) 免疫欠損状態の治療のための医薬製剤
US5369119A (en) Use of imexon as an immune suppressive and pharmaceutical compositions containing imexon
JPH06234636A (ja) インターロイキン8を阻害するためのレフルノミドの使用
AU619027B2 (en) Method for suppressing immune responses by administering imexon
Larionov Some biological and clinical results from the investigations of the chloroethylamines as anti-tumour drugs
NL194430C (nl) Niet-injecteerbaar farmaceutisch preparaat met anti-kankerwerking.
US4892876A (en) Method for inhibiting HIV and an pharmaceutical composition therefor
JPH01313433A (ja) 抗hiv剤
JPH05504550A (ja) 免疫抑制剤として有用なピリミジン生合成インヒビター
RU2816948C1 (ru) Применение пиностробина в качестве диуретического и креатининуретического средства
US20040142882A1 (en) Use of glycyrrhizin and its derivatives as RANTES inducers
JPH0435476B2 (enExample)
EP1623709A1 (en) Remedy for rheumatoid arthritis
SU1097334A1 (ru) Способ лечени ишемической болезни сердца
DE3844839C2 (de) Verwendung von Imexon als Immunsuppressivum
JPH0616561A (ja) 抗レトロウイルス剤
DE3844655A1 (de) Verwendung von imexon als immunsuppressivum
JPWO1989001778A1 (ja) 血小板減少予防及び治療剤
RU1638852C (ru) Способ лечения атопического дерматита
JPS60184012A (ja) 免疫調整剤
JPH07506564A (ja) 医薬的ペンタペプチド組成物およびその使用法
JPH0840916A (ja) 3ーオキシゲルミルプロピオン酸化合物を主成分とする疣贅の発症予防及び治療剤

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: ROCHE DIAGNOSTICS GMBH

Free format text: FORMER NAME WAS: BOEHRINGER MANNHEIM GMBH

PC Assignment registered

Owner name: AUTOONCONA PHARMA GMBH

Free format text: FORMER OWNER WAS: ROCHE DIAGNOSTICS GMBH